XML 54 R35.htm IDEA: XBRL DOCUMENT
v3.21.2

Collaborative Research and License Agreements (Details) |  |  |  | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Jul. 30, 2021 USD ($) agreement | Nov. 13, 2019 USD ($) agreement | Feb. 17, 2019 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  | $ 30,944,000 |  | $ 30,944,000 |  | $ 8,343,000 |
Deferred revenue, current |  |  |  | 14,015,000 |  | 14,015,000 |  | 8,343,000 |
Deferred revenue, noncurrent |  |  |  | 16,929,000 |  | 16,929,000 |  | 0 |
Ipsen Collaboration |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  | 19,197,000 |  | 19,197,000 |  | 0 |
Ipsen Collaboration | Ipsen HD |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Transaction price allocated |  |  |  | 10,793,000 |  | 10,793,000 |  |  |
Ipsen Collaboration | Ipsen AS |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Transaction price allocated |  |  |  | 9,207,000 |  | 9,207,000 |  |  |
AbbVie Collaboration |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  | 11,747,000 |  | 11,747,000 |  | 8,343,000 |
Collaboration Arrangement | Ipsen Collaboration |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Number of collaboration programs | agreement | 2 |  |  |  |  |  |  |  |
Proceeds from collaborators | $ 20,000,000 |  |  |  |  |  |  |  |
Pre-clinical milestone payment amount | 5,000,000 |  |  |  |  |  |  |  |
Development and regulatory milestone payment amount | 180,000,000 |  |  |  |  |  |  |  |
Commercial milestone payment amount | 762,000,000 |  |  |  |  |  |  |  |
Collaboration agreement, licensing fees incurred | $ 3,000,000 |  |  |  |  |  |  |  |
Collaboration agreement, termination notice period | 90 days |  |  |  |  |  |  |  |
Transaction price allocated | $ 20,000,000 |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  | 803,000 |  | 803,000 |  |  |
Deferred revenue |  |  |  | 19,197,000 |  | 19,197,000 |  |  |
Deferred revenue, current |  |  |  | 7,945,000 |  | 7,945,000 |  |  |
Deferred revenue, noncurrent |  |  |  | 11,252,000 |  | $ 11,252,000 |  |  |
Collaboration Arrangement | Ipsen Collaboration | Minimum |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Estimated timing of revenue recognition |  |  |  |  |  | 33 months |  |  |
Collaboration Arrangement | Ipsen Collaboration | Maximum |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Estimated timing of revenue recognition |  |  |  |  |  | 42 months |  |  |
Collaboration Arrangement | Ipsen Collaboration | Option Exercise Period after the Selection |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Collaboration option exercise fee | 10,000,000 |  |  |  |  |  |  |  |
Collaboration Arrangement | Ipsen Collaboration | Option Exercise Period that begins after the first Option Exercise Period |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Collaboration option exercise fee | $ 25,000,000 |  |  |  |  |  |  |  |
Collaboration Arrangement | AbbVie Collaboration |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Number of collaboration programs | agreement |  | 2 |  |  |  |  |  |  |
Collaboration option exercise fee |  | $ 10,000,000 |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  | $ 2,402,000 |  | $ 16,351,000 |  |
Deferred revenue |  |  |  | 11,747,000 |  | $ 11,747,000 |  |  |
Deferred revenue, current |  |  |  | 6,070,000 |  | 6,070,000 |  | $ 8,343,000 |
Deferred revenue, noncurrent |  |  |  | 5,677,000 |  | 5,677,000 |  |  |
Non-refundable upfront payment received for research agreement |  | 25,000,000 |  |  |  |  |  |  |
Collaboration option exercise fee |  | $ 10,000,000 |  |  |  |  |  |  |
Termination period upon written notice |  | 90 days |  |  |  |  |  |  |
Cumulative catch-up adjustment to revenue |  |  |  |  |  | $ (3,404,000) |  |  |
Cumulative catch-up adjustments to revenue, change in estimate |  |  |  | (4,480,000) |  |  |  |  |
Collaboration Arrangement | AbbVie Collaboration | Development and Commercialization License |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Collaboration option exercise fee |  | $ 15,000,000 |  |  |  |  |  |  |
Collaboration Arrangement | AbbVie Collaboration | Minimum |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Estimated timing of revenue recognition |  |  |  |  |  | 24 months |  |  |
Collaboration Arrangement | AbbVie Collaboration | Maximum |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Estimated timing of revenue recognition |  |  |  |  |  | 27 months |  |  |
Development milestone payment |  | 55,000,000 |  |  |  |  |  |  |
Product approval and launch milestone payment |  | 132,500,000 |  |  |  |  |  |  |
Sales milestone payment |  | $ 175,000,000 |  |  |  |  |  |  |
Collaboration Arrangement | Dermelix License Agreement |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  | $ 0 | $ 41,000 | $ 0 | $ 122,000 |  |
Deferred revenue |  |  |  |  |  |  |  |  | $ 0
Non-refundable upfront payment received for research agreement |  |  | $ 1,000,000 |  |  |  |  |  |
Collaboration development expenses |  |  | $ 1,000,000 |  |  |  |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Estimated Timing Of Revenue Recognition + References No definition available. + Details
Name: | xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition
Namespace Prefix: | xcur_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement, Extended Option, Additional Exercise Fee + References No definition available. + Details
Name: | xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Licensing Fees Incurred + References No definition available. + Details
Name: | xcur_CollaborationAgreementLicensingFeesIncurred
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Option, Exercise Fee + References No definition available. + Details
Name: | xcur_CollaborationAgreementOptionExerciseFee
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Termination Notice Period + References No definition available. + Details
Name: | xcur_CollaborationAgreementTerminationNoticePeriod
Namespace Prefix: | xcur_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement, Termination Period Upon Written Notice + References No definition available. + Details
Name: | xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice
Namespace Prefix: | xcur_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement, Transaction Price + References No definition available. + Details
Name: | xcur_CollaborationAgreementTransactionPrice
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration Agreement, Upfront Payment + References No definition available. + Details
Name: | xcur_CollaborationAgreementUpfrontPayment
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Development Expenses + References No definition available. + Details
Name: | xcur_CollaborationDevelopmentExpenses
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contract with Customer, Liability, Cumulative Catch-up Adjustments To Revenue, Change In Estimate + References No definition available. + Details
Name: | xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of Collaboration Programs + References No definition available. + Details
Name: | xcur_NumberofCollaborationPrograms
Namespace Prefix: | xcur_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Multiple-deliverable Arrangements, Collaboration Agreement, Pre-Clinical Milestone Payment + References No definition available. + Details
Name: | xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue Recognition, Multiple-deliverable Arrangements, Commercial Milestone Payment + References No definition available. + Details
Name: | xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue Recognition, Multiple-deliverable Arrangements, Development And Regulatory Milestone Payment + References No definition available. + Details
Name: | xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment + References No definition available. + Details
Name: | xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment + References No definition available. + Details
Name: | xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment + References No definition available. + Details
Name: | xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment
Namespace Prefix: | xcur_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xcur_CollaborationAgreementPerformanceObligationAxis=xcur_IpsenHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xcur_CollaborationAgreementPerformanceObligationAxis=xcur_IpsenASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xcur_ExercisePeriodAxis=xcur_ExercisePeriodOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xcur_ExercisePeriodAxis=xcur_ExercisePeriodTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xcur_DevelopmentandCommercializationLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xcur_ArrangementNameAxis=xcur_DermelixLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |